DOCSLIB.ORG

Histone H3k27ac Antibody, SNAP-Chip® Certified

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Histone H3k27ac Antibody, SNAP-Chip® Certified Histone H3K27ac Antibody, SNAP-ChIP® Certified Catalog No. 13-0045 Lot No. 21096003-01 Pack Size 50 µg Type Monoclonal Target Size 15 kDa Reactivity H, M, WR Host Mouse Format Aff. Pur. IgG Appl. ChIP, ChIP-Seq, L, IF Product Description: This antibody meets EpiCypher’s “SNAP-ChIP® Certified” criteria for specificity and efficient target enrichment in a ChIP experiment (<20% cross-reactivity across the panel, >5% recovery of target input). Histone H3 is one of the four proteins that are present in the nucleosome, the basic repeating subunit of chromatin, consisting of 147 base pairs of DNA wrapped around an octamer of core histone proteins (H2A, H2B, H3 and H4). This antibody reacts to H3K27ac and no cross reactivity Luminex Data: Histone H3K27ac antibody was assessed using a TM with other lysine acylations in the EpiCypher SNAP-ChIP K- Luminex® based approach employing dCypher Nucleosome K- AcylStat Panel (EpiCypher Catalog No. 16-9003). The panel AcylStat panel is detected. Antibody binding to H3K27ac in the comprises biotinylated designer nucleosomes (x-axis) individually context of phosphorylation at S28 (H3K27acS28ph) is inhibited coupled to uniquely identifiable Luminex MagPlex® beads. to varying degrees in Luminex and ChIP (see figures, right). Antibody binding to nucleosomes was tested in multiplex (23-plex) at a 1:4000 dilution, and detected with second layer anti-IgG*PE. Immunogen: Data was generated using a Luminex FlexMAP3D®. Data A synthetic peptide corresponding to histone H3 acetylated at normalized to relevant on-target (H3K27ac; set to 100) is shown. lysine 27. Formulation: Protein A affinity-purified antibody (1 mg/mL) in PBS pH 7.4, with 0.05% sodium azide. Storage and Stability: Stable for 1 year at -20°C from date of receipt. Application Notes: SNAP-ChIP-qPCR. Histone H3K27ac antibody (3 µg) was tested in 6 ChIP: 2 - 5 µg per 1x10 cells a native ChIP experiment using chromatin from K-562 cells (3 µg) with the SNAP-ChIP K-AcylStat Panel (EpiCypher Catalog No. L: 1:4000 19-3001) spiked-in prior to micrococcal nuclease digestion. IF: 1:500 Specificity (left y-axis) was determined by qPCR for the DNA barcodes corresponding to modified nucleosomes in the SNAP- References: ChIP panel (x-axis). Black bar represents antibody efficiency (right Grzybowski et al (2015) Mol Cell 58:886 y-axis; log scale) and indicates percentage of the target Shah et al (2018) Mol Cell 72:162 immunoprecipitated relative to input. Applications Key: ChIP: Chromatin immunoprecipitation; ChIP-seq: ChIP-sequencing; CUT&RUN: Cleavage Under Targets and Release Using Nuclease; CUT&Tag: Cleavage Under Targets and Tagmentation; E: ELISA; FACS: Flow cytometry; ICC: Immunocytochemistry; IF: Immunofluorescence; IHC: Immunohistochemistry; IP: Immunoprecipitation; L: Luminex; WB: Western Blot. Reactivity Key: B: Bovine; Ce: C. elegans; Ch: Chicken; Dm: Drosophila; Eu: Eukaryote; H: Human; M: Mouse; Ma: Mammal; R: Rat; Sc: S. cerevisiae; Sp: S. pombe; WR: Wide Range (predicted); X: Xenopus; Z: Zebrafish EpiCypher, Inc • Phone: 855-374-2461 • Fax: 855-420-6111 • www.epicypher.com Immunofluorescence. IF detection of H3K27ac in HeLa cells stained with H3K27ac antibody at a dilution of 1:500, followed by the addition of an anti-mouse secondary antibody conjugated to a fluorophore (left). The middle pannel shows staining of the nuclei with DAPI. A merge of the two stainings is shown on the right. Applications Key: ChIP: Chromatin immunoprecipitation; ChIP-seq: ChIP-sequencing; CUT&RUN: Cleavage Under Targets and Release Using Nuclease; CUT&Tag: Cleavage Under Targets and Tagmentation; E: ELISA; FACS: Flow cytometry; ICC: Immunocytochemistry; IF: Immunofluorescence; IHC: Immunohistochemistry; IP: Immunoprecipitation; L: Luminex; WB: Western Blot. Reactivity Key: B: Bovine; Ce: C. elegans; Ch: Chicken; Dm: Drosophila; Eu: Eukaryote; H: Human; M: Mouse; Ma: Mammal; R: Rat; Sc: S. cerevisiae; Sp: S. pombe; WR: Wide Range (predicted); X: Xenopus; Z: Zebrafish EpiCypher, Inc • Phone: 855-374-2461 • Fax: 855-420-6111 • www.epicypher.com.
Load more

Recommended publications
  • Genome-Wide Profiling of Active Enhancers in Colorectal Cancer
    Genome-wide proling of active enhancers in colorectal cancer Min Wu ( [email protected] ) Wuhan University https://orcid.org/0000-0003-1372-4764 Qinglan Li Wuhan University Xiang Lin Wuhan University Ya-Li Yu Zhongnan Hospital, Wuhan University Lin Chen Wuhan University Qi-Xin Hu Wuhan University Meng Chen Zhongnan Hospital, Wuhan University Nan Cao Zhongnan Hospital, Wuhan University Chen Zhao Wuhan University Chen-Yu Wang Wuhan University Cheng-Wei Huang Wuhan University Lian-Yun Li Wuhan University Mei Ye Zhongnan Hospital, Wuhan University https://orcid.org/0000-0002-9393-3680 Article Keywords: Colorectal cancer, H3K27ac, Epigenetics, Enhancer, Transcription factors Posted Date: December 10th, 2020 DOI: https://doi.org/10.21203/rs.3.rs-119156/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Genome-wide profiling of active enhancers in colorectal cancer Qing-Lan Li1, #, Xiang Lin1, #, Ya-Li Yu2, #, Lin Chen1, #, Qi-Xin Hu1, Meng Chen2, Nan Cao2, Chen Zhao1, Chen-Yu Wang1, Cheng-Wei Huang1, Lian-Yun Li1, Mei Ye2,*, Min Wu1,* 1 Frontier Science Center for Immunology and Metabolism, Hubei Key Laboratory of Cell Homeostasis, Hubei Key Laboratory of Developmentally Originated Disease, Hubei Key Laboratory of Intestinal and Colorectal Diseases, College of Life Sciences, Wuhan University, Wuhan, Hubei 430072, China 2Division of Gastroenterology, Department of Geriatrics, Hubei Clinical Centre & Key Laboratory of Intestinal and Colorectal Diseases, Zhongnan Hospital, Wuhan University, Wuhan, Hubei 430072, China #Equal contribution to the study. Contact information *Correspondence should be addressed to Dr. Min Wu, Email: [email protected], Tel: 86-27-68756620, or Dr.
    [Show full text]
  • Recognition of Histone Acetylation by the GAS41 YEATS Domain Promotes H2A.Z Deposition in Non-Small Cell Lung Cancer
    Downloaded from genesdev.cshlp.org on October 5, 2021 - Published by Cold Spring Harbor Laboratory Press Recognition of histone acetylation by the GAS41 YEATS domain promotes H2A.Z deposition in non-small cell lung cancer Chih-Chao Hsu,1,2,8 Jiejun Shi,3,8 Chao Yuan,1,2,7,8 Dan Zhao,4,5,8 Shiming Jiang,1,2 Jie Lyu,3 Xiaolu Wang,1,2 Haitao Li,4,5 Hong Wen,1,2 Wei Li,3 and Xiaobing Shi1,2,6 1Department of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA; 2Center for Cancer Epigenetics, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA; 3Dan L. Duncan Cancer Center, Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas 77030, USA; 4MOE Key Laboratory of Protein Sciences, Beijing Advanced Innovation Center for Structural Biology, Department of Basic Medical Sciences, School of Medicine, Tsinghua University, Beijing 100084, China; 5Tsinghua-Peking Joint Center for Life Sciences, Tsinghua University, Beijing 100084, China; 6Genetics and Epigenetics Graduate Program, The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, Texas 77030, USA Histone acetylation is associated with active transcription in eukaryotic cells. It helps to open up the chromatin by neutralizing the positive charge of histone lysine residues and providing binding platforms for “reader” proteins. The bromodomain (BRD) has long been thought to be the sole protein module that recognizes acetylated histones. Re- cently, we identified the YEATS domain of AF9 (ALL1 fused gene from chromosome 9) as a novel acetyl-lysine- binding module and showed that the ENL (eleven-nineteen leukemia) YEATS domain is an essential acetyl-histone reader in acute myeloid leukemias.
    [Show full text]
  • Epigenetics Analysis and Integrated Analysis of Multiomics Data, Including Epigenetic Data, Using Artificial Intelligence in the Era of Precision Medicine
    biomolecules Review Epigenetics Analysis and Integrated Analysis of Multiomics Data, Including Epigenetic Data, Using Artificial Intelligence in the Era of Precision Medicine Ryuji Hamamoto 1,2,*, Masaaki Komatsu 1,2, Ken Takasawa 1,2 , Ken Asada 1,2 and Syuzo Kaneko 1 1 Division of Molecular Modification and Cancer Biology, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan; [email protected] (M.K.); [email protected] (K.T.); [email protected] (K.A.); [email protected] (S.K.) 2 Cancer Translational Research Team, RIKEN Center for Advanced Intelligence Project, 1-4-1 Nihonbashi, Chuo-ku, Tokyo 103-0027, Japan * Correspondence: [email protected]; Tel.: +81-3-3547-5271 Received: 1 December 2019; Accepted: 27 December 2019; Published: 30 December 2019 Abstract: To clarify the mechanisms of diseases, such as cancer, studies analyzing genetic mutations have been actively conducted for a long time, and a large number of achievements have already been reported. Indeed, genomic medicine is considered the core discipline of precision medicine, and currently, the clinical application of cutting-edge genomic medicine aimed at improving the prevention, diagnosis and treatment of a wide range of diseases is promoted. However, although the Human Genome Project was completed in 2003 and large-scale genetic analyses have since been accomplished worldwide with the development of next-generation sequencing (NGS), explaining the mechanism of disease onset only using genetic variation has been recognized as difficult. Meanwhile, the importance of epigenetics, which describes inheritance by mechanisms other than the genomic DNA sequence, has recently attracted attention, and, in particular, many studies have reported the involvement of epigenetic deregulation in human cancer.
    [Show full text]
  • H3K27 Acetylation and Gene Expression Analysis Reveals Differences in Placental Chromatin Activity in Fetal Growth Restriction N
    Paauw et al. Clinical Epigenetics (2018) 10:85 https://doi.org/10.1186/s13148-018-0508-x RESEARCH Open Access H3K27 acetylation and gene expression analysis reveals differences in placental chromatin activity in fetal growth restriction N. D. Paauw1,6*, A. T. Lely1, J. A. Joles2, A. Franx1, P. G. Nikkels3, M. Mokry4 and B. B. van Rijn1,5,6* Abstract Background: Posttranslational modification of histone tails such as histone 3 lysine 27 acetylation (H3K27ac) is tightly coupled to epigenetic regulation of gene expression. To explore whether this is involved in placenta pathology, we probed genome-wide H3K27ac occupancy by chromatin immunoprecipitation sequencing (ChIP- seq) in healthy placentas and placentas from pathological pregnancies with fetal growth restriction (FGR). Furthermore, we related specific acetylation profiles of FGR placentas to gene expression changes. Results: Analysis of H3K27ac occupancy in FGR compared to healthy placentas showed 970 differentially acetylated regions distributed throughout the genome. Principal component analysis and hierarchical clustering revealed complete segregation of the FGR and control group. Next, we identified 569 upregulated genes and 521 downregulated genes in FGR placentas by RNA sequencing. Differential gene transcription largely corresponded to expected direction based on H3K27ac status. Pathway analysis on upregulated transcripts originating from hyperacetylated sites revealed genes related to the HIF-1-alpha transcription factor network and several other genes with known involvement in placental pathology (LEP, FLT1, HK2, ENG, FOS). Downregulated transcripts in the vicinity of hypoacetylated sites were related to the immune system and growth hormone receptor signaling. Additionally, we found enrichment of 141 transcription factor binding motifs within differentially acetylated regions.
    [Show full text]
  • Investigation of KRAS Dependency Bypass and Functional Characterization of All Possible KRAS Missense Variants
    Investigation of KRAS Dependency Bypass and Functional Characterization of All Possible KRAS Missense Variants The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:40050098 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA Investigation of KRAS Dependency Bypass and Functional Characterization of All Possible KRAS Missense Variants A dissertation presented by Seav Huong Ly to The Division of Medical Sciences in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the subject of Biological and Biomedical Sciences Harvard University Cambridge, Massachusetts April 2018 © 2018 Seav Huong Ly All rights reserved. Dissertation Advisor: William C. Hahn Seav Huong Ly Investigation of KRAS Dependency Bypass and Functional Characterization of All Possible KRAS Missense Variants Abstract The importance of oncogenic KRAS in human cancers have prompted intense efforts to target KRAS and its effectors. To anticipate the development of resistance to these strategies, we previously performed a genome-scale expression screen to identify genes that bypass KRAS oncogenic dependency. Here we test thirty-seven genes that scored over five standard deviations and find that overexpression of LIM homeobox 9 (LHX9), a transcription factor involved in embryonic development, robustly rescues the suppression of KRAS in vitro and xenograft models. Furthermore, LHX9 substantially decreases cell sensitivity to KRASG12C and MEK1/2 inhibitors in KRAS-dependent cells.
    [Show full text]
  • CUT&Runtools: a Flexible Pipeline for CUT&RUN Processing and Footprint Analysis
    Zhu et al. Genome Biology (2019) 20:192 https://doi.org/10.1186/s13059-019-1802-4 SOFTWARE Open Access CUT&RUNTools: a flexible pipeline for CUT&RUN processing and footprint analysis Qian Zhu1, Nan Liu2, Stuart H. Orkin2,3* and Guo-Cheng Yuan1* Abstract We introduce CUT&RUNTools as a flexible, general pipeline for facilitating the identification of chromatin-associated protein binding and genomic footprinting analysis from antibody-targeted CUT&RUN primary cleavage data. CUT&RUNTools extracts endonuclease cut site information from sequences of short-read fragments and produces single-locus binding estimates, aggregate motif footprints, and informative visualizations to support the high-resolution mapping capability of CUT&RUN. CUT&RUNTools is available at https://bitbucket.org/qzhudfci/cutruntools/. Introduction Results Mapping the occupancy of DNA-associated proteins, in- Overview cluding transcription factors (TFs) and histones, is central CUT&RUNTools takes paired-end sequencing read to determining cellular regulatory circuits. Conventional FASTQ files as the input and performs a set of analytical ChIP sequencing (ChIP-seq) relies on the cross-linking of steps: trimming of adapter sequences, alignment to the target proteins to DNA and physical fragmentation of reference genome, peak calling, estimation of cut matrix chromatin [1]. In practice, epitope masking and insolubil- at single-nucleotide resolution, de novo motif searching, ity of protein complexes may interfere with the successful motif footprinting analysis, direct binding site identifica- use of conventional ChIP-seq for some chromatin- tion, and data visualization (Fig. 1b). The outputs of the associated proteins [2–4]. CUT&RUN is a recently de- pipeline (Fig. 1c) are (1) an aggregate footprint capturing scribed native endonuclease-based method based on the the characteristics of chromatin-associated protein bind- binding of an antibody to a chromatin-associated protein ing (Fig.
    [Show full text]
  • Dynamics of Transcription-Dependent H3k36me3 Marking by the SETD2:IWS1:SPT6 Ternary Complex
    bioRxiv preprint doi: https://doi.org/10.1101/636084; this version posted May 14, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Dynamics of transcription-dependent H3K36me3 marking by the SETD2:IWS1:SPT6 ternary complex Katerina Cermakova1, Eric A. Smith1, Vaclav Veverka2, H. Courtney Hodges1,3,4,* 1 Department of Molecular & Cellular Biology, Center for Precision Environmental Health, and Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, 77030, USA 2 Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Prague, Czech Republic 3 Center for Cancer Epigenetics, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA 4 Department of Bioengineering, Rice University, Houston, TX, 77005, USA * Lead contact; Correspondence to: [email protected] Abstract The genome-wide distribution of H3K36me3 is maintained SETD2 contributes to gene expression by marking gene through various mechanisms. In human cells, H3K36 is bodies with H3K36me3, which is thought to assist in the mono- and di-methylated by eight distinct histone concentration of transcription machinery at the small portion methyltransferases; however, the predominant writer of the of the coding genome. Despite extensive genome-wide data trimethyl mark on H3K36 is SETD21,11,12. Interestingly, revealing the precise localization of H3K36me3 over gene SETD2 is a major tumor suppressor in clear cell renal cell bodies, the physical basis for the accumulation, carcinoma13, breast cancer14, bladder cancer15, and acute maintenance, and sharp borders of H3K36me3 over these lymphoblastic leukemias16–18. In these settings, mutations sites remains rudimentary.
    [Show full text]
  • EZH2 in Normal Hematopoiesis and Hematological Malignancies
    www.impactjournals.com/oncotarget/ Oncotarget, Vol. 7, No. 3 EZH2 in normal hematopoiesis and hematological malignancies Laurie Herviou2, Giacomo Cavalli2, Guillaume Cartron3,4, Bernard Klein1,2,3 and Jérôme Moreaux1,2,3 1 Department of Biological Hematology, CHU Montpellier, Montpellier, France 2 Institute of Human Genetics, CNRS UPR1142, Montpellier, France 3 University of Montpellier 1, UFR de Médecine, Montpellier, France 4 Department of Clinical Hematology, CHU Montpellier, Montpellier, France Correspondence to: Jérôme Moreaux, email: [email protected] Keywords: hematological malignancies, EZH2, Polycomb complex, therapeutic target Received: August 07, 2015 Accepted: October 14, 2015 Published: October 20, 2015 This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT Enhancer of zeste homolog 2 (EZH2), the catalytic subunit of the Polycomb repressive complex 2, inhibits gene expression through methylation on lysine 27 of histone H3. EZH2 regulates normal hematopoietic stem cell self-renewal and differentiation. EZH2 also controls normal B cell differentiation. EZH2 deregulation has been described in many cancer types including hematological malignancies. Specific small molecules have been recently developed to exploit the oncogenic addiction of tumor cells to EZH2. Their therapeutic potential is currently under evaluation. This review summarizes the roles of EZH2 in normal and pathologic hematological processes and recent advances in the development of EZH2 inhibitors for the personalized treatment of patients with hematological malignancies. PHYSIOLOGICAL FUNCTIONS OF EZH2 state through tri-methylation of lysine 27 on histone H3 (H3K27me3) [6].
    [Show full text]
  • Oncogenic Deregulation of EZH2 As an Opportunity for Targeted Therapy in Lung Cancer
    Published OnlineFirst June 16, 2016; DOI: 10.1158/2159-8290.CD-16-0164 RESEARCH ARTICLE Oncogenic Deregulation of EZH2 as an Opportunity for Targeted Therapy in Lung Cancer Haikuo Zhang1,2, Jun Qi1,2, Jaime M. Reyes1, Lewyn Li3, Prakash K. Rao3, Fugen Li3, Charles Y. Lin1, Jennifer A. Perry1, Matthew A. Lawlor1, Alexander Federation1, Thomas De Raedt2,4, Yvonne Y. Li1,2, Yan Liu1,2, Melissa A. Duarte3, Yanxi Zhang1,2, Grit S. Herter-Sprie1,2, Eiki Kikuchi1,2, Julian Carretero5, Charles M. Perou6, Jacob B. Reibel1,2, Joshiawa Paulk1, Roderick T. Bronson7, Hideo Watanabe1,2, Christine Fillmore Brainson8,9,10, Carla F. Kim8,9,10, Peter S. Hammerman1,2, Myles Brown2,3, Karen Cichowski2,4, Henry Long3, James E. Bradner1,2, and Kwok-Kin Wong1,2,11 Downloaded from cancerdiscovery.aacrjournals.org on September 29, 2021. © 2016 American Association for Cancer Research. Published OnlineFirst June 16, 2016; DOI: 10.1158/2159-8290.CD-16-0164 ABSTRACT As a master regulator of chromatin function, the lysine methyltransferase EZH2 orchestrates transcriptional silencing of developmental gene networks. Overex- pression of EZH2 is commonly observed in human epithelial cancers, such as non–small cell lung carci- noma (NSCLC), yet definitive demonstration of malignant transformation by deregulatedEZH2 remains elusive. Here, we demonstrate the causal role of EZH2 overexpression in NSCLC with new genetically engineered mouse models of lung adenocarcinoma. Deregulated EZH2 silences normal developmental pathways, leading to epigenetic transformation independent of canonical growth factor pathway acti- vation. As such, tumors feature a transcriptional program distinct from KRAS- and EGFR-mutant mouse lung cancers, but shared with human lung adenocarcinomas exhibiting high EZH2 expression.
    [Show full text]
  • Quantitative Proteomic Characterization and Comparison of T Helper 17 and Induced Regulatory T Cells
    METHODS AND RESOURCES Quantitative proteomic characterization and comparison of T helper 17 and induced regulatory T cells Imran Mohammad1,2, Kari Nousiainen3, Santosh D. Bhosale1,2, Inna Starskaia1,2, Robert Moulder1, Anne Rokka1, Fang Cheng4, Ponnuswamy Mohanasundaram4, John E. Eriksson4, David R. Goodlett5, Harri LaÈhdesmaÈki3, Zhi Chen1* 1 Turku Centre for Biotechnology, University of Turku and Åbo Akademi University, Turku, Finland, 2 Turku Doctoral Programme of Molecular Medicine, University of Turku, Turku, Finland, 3 Department of Computer a1111111111 Science, Aalto University, Espoo, Finland, 4 Cell Biology, Biosciences, Faculty of Science and Engineering, a1111111111 Åbo Akademi University, Turku, Finland, 5 Department of Pharmaceutical Sciences, University of Maryland a1111111111 School of Pharmacy, Baltimore, Maryland, United States of America a1111111111 a1111111111 * [email protected] Abstract OPEN ACCESS The transcriptional network and protein regulators that govern T helper 17 (Th17) cell differ- Citation: Mohammad I, Nousiainen K, Bhosale SD, entiation have been studied extensively using advanced genomic approaches. For a better Starskaia I, Moulder R, Rokka A, et al. (2018) understanding of these biological processes, we have moved a step forward, from gene- to Quantitative proteomic characterization and protein-level characterization of Th17 cells. Mass spectrometry±based label-free quantita- comparison of T helper 17 and induced regulatory T cells. PLoS Biol 16(5): e2004194. https://doi.org/ tive (LFQ) proteomics analysis were made of in vitro differentiated murine Th17 and induced 10.1371/journal.pbio.2004194 regulatory T (iTreg) cells. More than 4,000 proteins, covering almost all subcellular compart- Academic Editor: Paula Oliver, University of ments, were detected. Quantitative comparison of the protein expression profiles resulted in Pennsylvania Perelman School of Medicine, United the identification of proteins specifically expressed in the Th17 and iTreg cells.
    [Show full text]
  • Differential Chromatin Binding of the Lung Lineage Transcription Factor NKX2-1 Resolves Opposing Murine Alveolar Cell Fates in Vivo ✉ Danielle R
    ARTICLE https://doi.org/10.1038/s41467-021-22817-6 OPEN Differential chromatin binding of the lung lineage transcription factor NKX2-1 resolves opposing murine alveolar cell fates in vivo ✉ Danielle R. Little1,2, Anne M. Lynch1,3, Yun Yan 2, Haruhiko Akiyama4, Shioko Kimura 5 & Jichao Chen 1 Differential transcription of identical DNA sequences leads to distinct tissue lineages and then multiple cell types within a lineage, an epigenetic process central to progenitor and stem 1234567890():,; cell biology. The associated genome-wide changes, especially in native tissues, remain insufficiently understood, and are hereby addressed in the mouse lung, where the same lineage transcription factor NKX2-1 promotes the diametrically opposed alveolar type 1 (AT1) and AT2 cell fates. Here, we report that the cell-type-specific function of NKX2-1 is attributed to its differential chromatin binding that is acquired or retained during development in coordination with partner transcriptional factors. Loss of YAP/TAZ redirects NKX2-1 from its AT1-specific to AT2-specific binding sites, leading to transcriptionally exaggerated AT2 cells when deleted in progenitors or AT1-to-AT2 conversion when deleted after fate commitment. Nkx2-1 mutant AT1 and AT2 cells gain distinct chromatin accessible sites, including those specific to the opposite fate while adopting a gastrointestinal fate, suggesting an epigenetic plasticity unexpected from transcriptional changes. Our genomic analysis of single or purified cells, coupled with precision genetics, provides an epigenetic basis for alveolar cell fate and potential, and introduces an experimental benchmark for deciphering the in vivo function of lineage transcription factors. 1 Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
    [Show full text]
  • Chip Sequencing
    DNBseqTM SERVICE OVERVIEW ChIP Sequencing Service Description Project Workflow ChIP Sequencing is widely used to analyze protein interactions with DNA. We care for your samples from the start through It combines chromatin immunoprecipitation (ChIP) with massively parallel to the result reporting. Highly experienced DNA sequencing to identify binding sites of DNA-associated proteins, laboratory professionals follow strict quality and can be used to precisely map global binding sites for any protein of procedures to ensure high quality results. abundant information in comparison with array-based ChIP-chip. SAMPLE PREPARATION and customized bioinformatics services to suit your specific research needs. Sample QC Confidence: Great correlation with HiSeq data. Low input: As low as 5ng ChIP-ed DNA/sample for human sample. Comprehensive analysis: Correlation analysis between ChIP-Seq and RNA-seq. LIBRARY CONSTRUCTION Sequencing Service Specification The BGI ChIP-Seq Service will be performed with BGI’s DNBseq Library QC sequencing technology, featuring combinatorial probe-anchor synthesis (cPAS) and DNA Nanoballs (DNB) technology[1] for superior data quality. SEQUENCING • 50bp Single-end sequencing reads • Standard output 20 Million reads per sample Sequencing QC • Clean data and bioinformatics analysis are available in standard file formats • Available data storage and bioinformatics RAW DATA OUTPUT applications • Cloud-based data storage and delivery system Data QC Turn Around Time BIOINFORMATICS • Typical 25 working days from sample QC acceptance ANALYSIS to final data delivery • Expedited services are available, contact your local BGI specialist for details Delivery QC DNBseqTM ChIP-Seq Data Analysis In addition to clean data output, BGI oers a range of standard, advanced and customized bioinformatics pipelines for your ChIP-Seq analysis project, including the correlation analysis of dierential expression genes and peak-related genes.
    [Show full text]